Latest Commercialization News

Elixir Energy has successfully drilled the Lorelle-3 pilot well to 3,580 metres in Queensland’s Taroom Trough, intersecting multiple Permian hydrocarbon reservoirs including a thick section of the primary Tinowon ‘Dunk’ Sandstone. Wireline logging and upcoming stimulation tests aim to confirm commercial gas flow potential.

Legend Mining’s latest geophysical surveys at Pyrophyllite Hill within the Pinnacle Well Project reveal promising signs of gold mineralisation alongside confirmed industrial mineral potential, setting the stage for upcoming drilling campaigns.

Eden Innovations has taken a major step in strengthening its balance sheet by converting a $2.2 million loan into equity, positioning the company debt free and ready to accelerate growth.

Finder Energy has successfully completed the Front-End Engineering Design for its Kuda Tasi and Jahal subsea development, setting the stage for a Final Investment Decision by mid-2026.

Sarytogan Graphite Limited has upgraded its Mineral Resource Estimate to include 5.4 million tonnes of Measured graphite, underpinning a multi-decade mine life in Kazakhstan. This milestone supports the ongoing Definitive Feasibility Study due mid-2026.

Australian Clinical Labs reported a modest revenue dip but achieved growth in earnings and margins in 1H26, while updating FY26 guidance and addressing wage increases mandated by the Fair Work Commission.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

Galilee Energy has launched an offer of up to 464 million new options to participants in its recent $6.5 million placement, aiming to bolster exploration funding and working capital. The options, exercisable at $0.011 each over three years, come amid significant operational and market risks.

BrainChip has launched its AKD2500 silicon development project, advancing its Akida™ 2.0 neuromorphic AI platform with a $2.5 million investment and prototype expected by Q3 2026.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.